Thursday, June 26, 2014
SHX Vaccines is taking a new approach to vaccinating
against meningitis-preventing meningococci from binding to host cells in the
first place. The company's university collaborators have shown proof of concept
for the approach in human tissue explants, including efficacy against serotype
B-the bacteria's most common but most intractable subgroup.1
It remains unclear how pilE and pilV act in concert to
initiate bacterial adhesion to CD147.
Baas, T. SciBX 7(25);
doi:10.1038/scibx.2014.727 Published online June 26, 2014
1. Bernard, S.C. et al. Nat. Med.; published
online June 1, 2014; doi:10.1038/nm.3563
Contact: Sandrine Bourdoulous, Institut National de la
Santé et de la Recherche Médicale (INSERM), Paris, France
AND INSTITUTIONS MENTIONED
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Institut National de la Santé et de la Recherche Médicale, Paris, France
(NYSE:NVS; SIX:NOVN), Basel, Switzerland
Paris Cardiovascular Research Center, Paris, France
(NYSE:PFE), New York, N.Y.
University Paris Descartes, Paris, France